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Abstract
Background: Colorectal cancer (CRC) screening remains underused, especially in safety-net 
systems. The objective of this study was to determine the effectiveness, costs, and cost-
effectiveness of organized outreach using fecal immunochemical tests (FITs) compared with usual 
care.
Methods: Patients age 50–75 years eligible for CRC screening from eight participating primary 
care safety-net clinics were randomly assigned to outreach intervention with usual care vs usual 
care alone. The intervention included a mailed postcard and call, followed by a mailed FIT kit, and 
a reminder phone call if the FIT kit was not returned. The primary outcome was screening 
participation at 1 year and a microcosting analysis of the outreach activities with embedded long-
term cost-effectiveness of outreach. All statistical tests were two-sided.
Results: A total of 5386 patients were randomly assigned to the intervention group and 5434 to 
usual care. FIT screening was statistically significantly higher in the intervention group than in the 
control group (57.9% vs 37.4%, P < .001; difference = 20.5%, 95% confidence interval = 18.6% to 
22.4%). In the intervention group, FIT completion rate was higher in patients who had previously 
completed a FIT vs those who had not (71.9% vs 35.7%, P < .001). There was evidence of effect 
modification of the intervention by language, and clinic. Outreach cost approximately $23 per 
patient and $112 per additional patient screened. Projecting long-term outcomes, outreach was 
estimated to cost $9200 per quality-adjusted life-year gained vs usual care.
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Conclusion: Population-based management with organized FIT outreach statistically 
significantly increased CRC screening and was cost-effective in a safety-net system. The 
sustainability of the program and any impact of economies of scale remain to be determined.
Colorectal cancer (CRC) is a leading cause of cancer deaths, yet it is often preventable (1,2). 
Screening remains underused, especially among racial and/or ethnic minorities and low-
income populations (3). As a strategy, fecal immunochemical testing (FIT) is accepted by 
many patients (4) and increasingly used to support population-level screening (5,6). Because 
FIT testing can be performed at home, CRC screening participation is an ideal preventive 
health outcome to test the effectiveness and cost of an organized approach to population-
level outreach.
We sought to examine the effectiveness and cost of a centrally organized outreach care 
model, using direct mailing of FIT kits, to improve CRC screening in partnership with 
multiple primary care clinics serving safety-net patients. Studies to date have examined FIT 
mailing, but data are scarce regarding implementation effectiveness across varying clinics 
and populations, the influence of prior screening behavior, and the health economics of such 
programs. In this study, we quantify the effectiveness of a FIT-based CRC screening 
outreach intervention within an integrated safety-net system, we determine the time and 
costs required to deliver the intervention, and we project the program’s clinical impact, cost, 
and cost-effectiveness over the long term.
Methods
Study Setting
We performed a multisite, pragmatic, randomized, controlled trial in a publicly funded 
integrated safety-net health system providing services to low-income populations, the San 
Francisco Health Network (SFHN). The SFHN consists of 12 adult primary care clinics and 
one specialty medical center, Zuckerberg San Francisco General Hospital. These clinics 
share an electronic health record system and a centralized clinical laboratory and refer to one 
gastroenterology unit.
The study team introduced the study protocol to the medical directors, and eight agreed to 
allow random assignment of empaneled patients to receive outreach intervention vs usual 
care. Providers and staff were blinded to which patients were assigned to the outreach 
intervention, although provision of the FIT kit by the outreach team was documented in the 
electronic medical records. Waiver of informed consent was approved by the University of 
California San Francisco (institutional review board, 14–14861, NCT02613260), and 
patients were enrolled between January 2016 and October 2017.
For asymptomatic patients at average risk for CRC, stool-based screening is standard 
practice within the SFHN. Colonoscopy is recommended for patients at increased risk for 
CRC and those with abnormal stool-based tests. The FIT brands used in the health system 
included the OC-Light, which transitioned to OC-Auto Sensor (Polymedco CDP, LLC, 
Cortlandt Manor, NY) in 2016.
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Study Population
Patients age 50–75 years who were not up to date with CRC screening were eligible. 
Previously screened patients became eligible 365 days after previous negative FIT, 5 years 
after previous normal sigmoidoscopy, and 10 years after previous normal colonoscopy. 
Patients were excluded if they were homeless, had an abnormal FIT but no colonoscopy, 
colectomy, late-stage cancer, or advanced comorbidities (Figure 1).
Study Intervention
Patients were stratified by clinic, sex, race and/or ethnicity, and prior FIT participation and 
then randomly assigned 1: 1 to outreach intervention or usual care (Figure 1). The study 
team performed the outreach intervention. Outreach included an informational postcard and 
up to two phone calls, followed by mailing of a FIT kit packet, and then up to two reminder 
phone calls if the FIT kit was not returned after 2 weeks. Phone calls were performed during 
work hours with interpreter services available for all languages. The FIT kit packet included 
a letter with basic information about CRC, the FIT kit, glove, lab requisition, prepaid return 
envelope, and low-literacy wordless instructions for completing the test (7). The reasons for 
not returning the FIT kit were collected during reminder calls. Written materials were 
provided in English, Spanish, and Chinese.
Usual Care
Usual care was at the discretion of providers in the eight participating clinics. Clinics used 
medical assistants to offer FIT during patient visits, and panel management software (i2i 
Population Health, Franklin, TN) was available to identify patients due for screening. 
Abnormal FIT results are automatically routed to the patient’s primary care provider; 
follow-up of abnormal FIT results and referral to colonoscopy was at the discretion of 
primary care providers.
Outcomes
FIT screening status was ascertained by laboratory test completion and results. Health 
service utilization is populated into the electronic medical records. FIT completion and 
endoscopy procedures were available in real time and were extracted and linked to the study 
database to ascertain the clinical outcomes.
Cost Accounting
Prospective cost accounting using a microcosting method was embedded in the intervention 
arm. Microcosting, which accounts for all the individual components that contribute to an 
overall cost, distinguished the costs for one-time initial implementation, including initial 
capital costs and staff training, vs ongoing outreach activities. Staff recorded time spent per 
specific outreach activity, based on categories previously defined by the Centers for Disease 
Control and Prevention (8), and normalized by the number of patients receiving outreach 
during the three outreach cycles (February–March 2016, September–October 2016, and 
June–July 2017). Average costs per patient were estimated based on individual salaries and 
benefits of responsible staff and average costs of materials per patient.
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Short-Term and Projected Long-Term Cost-Effectiveness
Short-term cost-effectiveness was estimated as the cost per additional patient screened, a 
measure that incorporates the impact of the intervention on screening participation. To 
estimate the long-term clinical and economic impact of outreach, we adapted our validated 
decision analytic model of CRC screening (Supplementary Methods and Supplementary 
Figure 1, available online) (9,10). In brief, we modeled outreach vs usual care with the 
screening rates at 1 year and costs observed in the current study (Supplementary Table 1, 
available online). The simulation’s time horizon was through age 100 years or death, with 
screening offered from age 50 to 80 years. Based on screening behavior through the second 
year after randomization in this trial as well as published literature (11–15), we estimated the 
fractions of consistent, intermittent, and never-screeners over time under outreach vs usual 
care (10). We accounted for imperfect follow-up colonoscopy rates after abnormal FIT 
results, which was estimated to be 55.6% based on published data from the SFHN (16). All 
screening and treatment costs were based on 2018 Medicare reimbursement rates. Primary 
model outcomes were discounted quality-adjusted life-years (QALYs) and costs per patient. 
Sensitivity analyses explored the range of intervention effects across individual clinics, a 
range of outreach program costs, and the potential impact of navigation (17,18) on follow-up 
colonoscopy completion after abnormal FIT.
Statistical Analysis
Patient demographic characteristics were summarized by treatment group using proportions 
or means and SD and compared using χ2 or t tests, as appropriate. All tests were two-sided, 
and a P value of less than .05 was considered statistically significant.
The primary outcome was completion of FIT screening and summarized by the proportions 
of patients who were up to date 1 year after study enrollment. This intention-to-treat analysis 
included all patients assigned to outreach, regardless of whether FIT kits were mailed. 
Evidence for modification of the effect of the outreach intervention by clinic, sex, race 
and/or ethnicity, insurance coverage, and language was examined using logistic models with 
interaction terms. Patients who were lost to follow-up, defined as absence of an encounter 
over 2 years or SFHN no longer designated as their medical home, were assumed not to have 
completed FIT screening if the patient had not completed screening before being lost to 
follow-up. For illustrative purposes, a cumulative incidence plot was used to estimate the 
proportions up to date over time. The between-group difference in proportions was 
determined and the inverse of the between-group difference was used to estimate the number 
needed to treat. In addition, we conducted a per-protocol analysis excluding patients who 
were not sent a FIT kit; reasons included an unreliable address (returned postcard), no longer 
in the health network, death, or screening deferred (Figure 1).
For patients who had abnormal FIT results and had at least 6 months of follow-up time, we 
examined the colonoscopy completion rate within the intervention and usual-care groups. 
Finally, during reminder calls, the reasons for not being up to date were collected and 
categorized (eg, forgot, already returned the test, needed a new test). We examined the FIT 
kit return rate after the call, by category.
Somsouk et al. Page 4
J Natl Cancer Inst. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
With more than 10 000 patients, the overall study provided 80% power in two-sided tests 
with a type-I error rate of 5% to detect a between-group difference of 2.7 percentage points. 
Within subgroups defined by race, language preferences, and clinic, minimum detectable 
between-group differences ranged from 5.6 to 13.4 percentage points, depending on the size 
of the subgroup and the completion rate among controls. We used Stata (version 15.1; 
StataCorp LP, College Station, TX) and SAS (version 9.4; SAS Institute Inc, Cary, NC) for 
all statistical analyses, and TreeAge Pro (TreeAge Software, Williamstown, MA) for cost-
effectiveness analyses.
Results
Patient Demographics
A total of 18 509 patients age 50–75 years were empaneled in the eight SFHN primary care 
clinics, and 12 848 (69.4%) were eligible for CRC screening and for random assignment 
(Figure 1). The leading reasons for exclusion were colonoscopy within the last 10 years 
(14.5%) and previously abnormal FIT (6.5%) (Figure 1).
Between January 2016 and October 2017, 10 820 patients were enrolled from eight clinic 
sites: 5434 patients into usual care and 5386 patients into outreach intervention. 
Demographic characteristics varied by clinic (Table 1). The distribution of age, sex, race, 
and insurance type were similar among the usual care and intervention groups (data not 
shown).
Effect of Organized Outreach to Increase FIT Participation
Over 1 year, 11.8% patients were lost to follow-up; this difference was not statistically 
significantly different between groups (11.5% in outreach vs 12.2% in usual care, P = .25). 
Of patients in the intervention group, 57.9% (95% confidence interval [CI] = 56.6% to 
59.3%) had returned the FIT kit by 1 year vs 37.4% (95% CI = 36.1% to 38.7%) (difference 
of 20.5%, 95% CI = 18.6% to 22.4%; P < .001; Table 2 and Figure 2). Even at day 28, 
outreach led to a statistically significant increase in FIT completion (13.3% vs 5.1%; P 
< .001; data not shown). Most of the screening participation following the outreach 
intervention occurred within 90 days of the intervention, whereas screening participation 
under usual care was distributed more evenly over time (Figure 2). The number needed to 
receive outreach for an additional patient screened was 4.8.
In a per-protocol analysis excluding 1143 patients who were not mailed FIT kits (Figure 1), 
FIT completion increased by 10.7 percentage points to 68.6% (95% CI = 67.2% to 69.9%). 
The between-group difference in participation increased to 31.3%, with a number needed to 
mail a FIT kit for an additional patient screened of 3.2.
Effect of Organized Outreach by Clinic
The effect of the outreach intervention consistently increased screening participation; 
however, the magnitude of the effect differed by clinic with evidence of effect modification 
(odds ratio [OR] range = 1.75–3.54; percentage point increase across clinics, 13.6% to 
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30.0%) (Table 2). FIT completion by clinic ranged from 49.9% to 67.4% in the intervention 
arm vs 26.2% to 44.2% in usual care (Table 2).
Effect of Organized Outreach by Patient Subgroup
There was an increase in FIT participation among patients assigned to outreach intervention 
vs usual care across all patient subgroups (Table 2). The subgroups with highest screening 
participation at 1 year were ethnic minorities (eg, Asian 69.3% and Hispanic 65.2%), 
patients with Healthy Worker insurance (70.1%), and patients who used non-English 
languages (Chinese 80.0% and Spanish 68.2%), with language showing evidence of effect 
modification. Patients who had previously completed a FIT were more likely to complete a 
FIT than those with no record of prior FIT completion (70.2% vs 34.8%; P < .001). OC-
Light transitioned to OC-Sensor during the study period. There was no statistically 
significant difference in completion rates by the two brands of FIT tests after adjustment for 
clinical covariates.
Colonoscopy Follow-up After Abnormal FIT
Colonoscopy completion was ascertained for patients with abnormal FIT results. Among 
patients who had at least 6 months of follow-up time after an abnormal FIT, a similar 
proportion of patients in both groups completed a colonoscopy: 51.0% (106 of 208) of 
patients in intervention vs 51.4% (57 of 111) in usual care (P = .94) (Supplementary Table 2, 
available online).
Reasons for Not Being Up to Date
At the time of the reminder call, the most common reasons stated for not being up to date 
were forgot/not a priority/busy (26.4%), patients reporting that they already returned or 
completed the test but had not mailed it yet (24.0%), did not receive/lost/damaged test 
(15.3%), and did not understand how to complete the test (10.6%) (Supplementary Table 3, 
available online). After the reminder call, the percentage of patients becoming up to date 
according to stated reasons were as follows: forgot/not a priority/busy (62.7%), already 
returned or completed the test (90.7%), did not receive test/lost test/test damaged (61.8%), 
and did not understand how to complete the test (77.4%).
Cost Accounting
Initial start-up implementation costs, including equipment and training, totaled $15 997 
(Supplementary Table 4, available online). The average time spent in outreach per patient 
(range = 21.5–24.2 minutes) and the average total outreach cost per patient (range = $22.2–
$24.1) did not change substantially across the three sampling cycles (Table 3). Labor costs 
exceeded material costs (Supplementary Figure 2, available online), and 86%–91% of labor 
time was devoted to direct patient activities as opposed to program-related activities, 
including 25%–36% of time spent on phone calls (Table 3; Supplementary Figure 3, 
available online).
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Short-Term and Projected Long-Term Cost-Effectiveness
The approximate outreach cost of $23 per patient, coupled with the absolute increase in FIT 
completion rate of 20.5% at 1 year, translated to a cost of $112 per additional patient 
screened. Projecting the clinical trial results over the long term, and incorporating the 
observed implementation and ongoing costs of outreach, the estimated QALYs and cost per 
patient were 19.6259 QALYs and $2960 with outreach, and 19.6103 QALYs and $2816 with 
usual care, yielding a cost of $9200 per QALY gained with outreach (Supplementary Table 
5, available online).
In clinic-level sensitivity analyses across the range of gains in FIT participation rates (Table 
2), the cost of outreach was $900–$23 400 per QALY gained (Supplementary Table 5, 
available online). If outreach cost decreased to less than $14 per patient, outreach achieved 
better outcomes at lower costs than usual care. At outreach costs of $50 per patient, outreach 
cost $37 400 per QALY gained. If screening outreach was coupled with navigation to 
increase completion of colonoscopy after abnormal FIT from 55% to a hypothetical 75% 
with navigation, as has been reported for navigation with screening colonoscopy, then 
outreach plus navigation cost $3000 per QALY gained.
Discussion
In this trial of an organized outreach intervention, implemented in partnership with eight 
primary care clinics, direct mailing of FIT kits to patients not up to date with CRC screening 
statistically significantly increased CRC screening participation at each site. An estimated 
three to five additional individuals needed to receive outreach to increase screening by one. 
Because this study was conducted in multiple clinics with diverse populations, the 
effectiveness reflects a range of real-world estimates of the initiative depending on the 
clinical setting. The prospective cost accounting embedded in the trial provides real-world 
estimates of the staff time, resources, and costs required to deliver outreach. Our long-term 
cost-effectiveness analysis, informed by the clinical results of the study and the cost 
accounting, suggests that organized outreach is highly cost-effective across multiple clinical 
scenarios.
The cost to perform outreach for one individual ($23) and the cost per additional patient 
screened ($112) both appear acceptable at face value based on the established clinical 
benefits of CRC screening. Our cost of outreach are in line or lower than prior estimates, 
which could be attributed to a central structure with increased scale (19,20). In addition, our 
estimate of the long-term cost-effectiveness of outreach ($9200 per QALY gained vs usual 
care in the base case) is novel and within acceptable ranges for services adopted by health 
systems (21). Moreover, we used conservative assumptions for colonoscopy completion at 
55.6% after abnormal FIT that are based on an earlier study in this safety-net health system 
(16), and that are consistent with the rates observed in other safety-net settings (22,23). 
When outreach effectiveness was varied across the range observed across all clinics, 
organized outreach to improve CRC screening remained highly cost-effective. To further 
drive down cost, economies of scale and automation might be achieved through use of 
communication and mailing vendors, which could be cost saving at outreach costs of less 
than $14 per patient in our models.
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Organized outreach has been shown to be effective in several private and public health 
settings (24–30). By randomly assigning patients in eight clinical sites, this study may be the 
most comprehensive to date to characterize the range of effectiveness achieved across clinics 
and demography and prior testing behavior while accounting for implementation and 
operation costs and long-term cost-effectiveness. This level of detail in diverse safety-net 
clinics extends the knowledge by demonstrating that a centrally administered FIT outreach 
program is highly cost-effective. We expect the comprehensive nature of this study to inform 
health-care systems as they address population-wide CRC screening.
We attempted to understand barriers to screening faced by patients in our health system. Our 
results suggest that reminder phone calls addressing patient concerns may improve 
completion, as reported previously by others (30,31). However, there remains a proportion of 
patients who do not complete screening despite outreach and follow-up efforts. The 
intervention consistently raised the level of screening, but it did not close disparity gaps.
Our study has limitations. First, the clinics that did not participate in this study tended to 
have CRC screening rates of 70% or higher. The impact of organized outreach would have 
been more modest among these clinics, but it could have offset clinic staff time currently 
dedicated to panel management and screening. As such, it is possible that the results do not 
generalize to other health-care settings and populations. Second, there were patients 
excluded from this study based on homelessness and advanced comorbidities, who are less 
likely to be screened and could have lowered the screening rates. Third, stool-based 
screening programs address screening, but colonoscopy completion for patients with 
abnormal screening results is necessary for screening to reduce CRC incidence and 
mortality; our intervention did not address colonoscopy follow-up, which was similar 
between both groups. Nonetheless, our long-term simulation suggests that outreach remains 
highly cost-effective even with suboptimal follow-up colonoscopy rates. Lastly, we have not 
examined the individual contribution of each component of the intervention, although prior 
studies have attempted to disentangle these components (31,32).
In conclusion, organized outreach using direct mailing of FIT kits can improve CRC 
screening, and the favorable health economic results support the widespread adoption of this 
service, assuming that the results generalize to other locations. Reimbursement models that 
facilitate population-level preventive health management strategies could further improve 
CRC screening.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Funding
This work was supported by the Centers for Disease Control and Prevention (CDC) U48DP004998 (SIP 14-012), 
the UCSF Academic Research Systems, and the National Center for Advancing Translational Sciences, National 
Institutes of Health, through UCSF-CTSI Grant Number UL1 TR991872, and the SF Cancer Initiative.
The funds from CDC were granted through a cooperative agreement in which we worked closely with a CDC 
program officer to design and implement the study. The findings and conclusions in this report are those of the 
authors and do not necessarily represent the official position of the CDC or US National Institutes of Health.
Somsouk et al. Page 8
J Natl Cancer Inst. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7–30. 
[PubMed: 26742998] 
2. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US Preventive 
Services Task Force Recommendation Statement. JAMA. 2016;315(23):2564–2575. [PubMed: 
27304597] 
3. Gupta S, Sussman DA, Doubeni CA, et al. Challenges and possible solutions to colorectal cancer 
screening for the underserved. J Natl Cancer Inst. 2014; 106(4):dju032. [PubMed: 24681602] 
4. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening. Arch Intern Med. 
2012;172(7):575–582. [PubMed: 22493463] 
5. Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing 
colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 
2015;121(18):3221–3229. [PubMed: 25995082] 
6. Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer 
incidence and mortality in a large, community-based population. Gastroenterology. 
2018;155(5):1383–1391.e5. [PubMed: 30031768] 
7. Wang A, Rachocki C, Shapiro JA, et al. Low-literacy level instructions and reminder calls improve 
patient handling of fecal immunochemical test samples [published online ahead of print Nov. 29, 
2018]. Clin Gastroenterol Hepatol. 2018. doi:10.1016/j.cgh.2018.11.050.
8. Subramanian S, Tangka FK, Hoover S, et al. Clinical and programmatic costs of implementing 
colorectal cancer screening: evaluation of five programs. Eval Program Plann. 2011;34(2):147–153. 
[PubMed: 21036399] 
9. Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and 
economic outcomes and health services demand. Gastroenterology. 2005;129(4):1151–1162. 
[PubMed: 16230069] 
10. Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget 
stool DNA test to screen for colorectal neoplasia. Gastroenterology. 2016;151(3):427–439.e6. 
[PubMed: 27311556] 
11. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 
rounds of annual screening. Ann Intern Med. 2016;164(7): 456–463. [PubMed: 26811150] 
12. Duncan A, Turnbull D, Wilson C, et al. Behavioural and demographic predictors of adherence to 
three consecutive faecal occult blood test screening opportunities: a population study. BMC Public 
Health. 2014;14:238. [PubMed: 24606951] 
13. Lo SH, Halloran S, Snowball J, et al. Colorectal cancer screening uptake over three biennial 
invitation rounds in the English bowel cancer screening programme. Gut. 2015;64(2):282–291. 
[PubMed: 24812001] 
14. Kapidzic A, Grobbee EJ, Hol L, et al. Attendance and yield over three rounds of population-based 
fecal immunochemical test screening. Am J Gastroenterol. 2014;109(8):1257–1264. [PubMed: 
24980879] 
15. Wong MC, Ching JY, Lam TY, et al. Prospective cohort study of compliance with faecal 
immunochemical tests for colorectal cancer screening in Hong Kong. Prev Med. 2013;57(3):227–
231. [PubMed: 23732241] 
16. Issaka RB, Singh MH, Oshima SM, et al. Inadequate utilization of diagnostic colonoscopy 
following abnormal FIT results in an integrated safety-net system. Am J Gastroenterol. 
2017;112(2):375–382. [PubMed: 28154400] 
17. Ladabaum U, Mannalithara A, Jandorf L, et al. Cost-effectiveness of patient navigation to increase 
adherence with screening colonoscopy among minority individuals. Cancer. 2015;121(7):1088–
1097. [PubMed: 25492455] 
18. Jandorf L, Stossel LM, Cooperman JL, et al. Cost analysis of a patient navigation system to 
increase screening colonoscopy adherence among urban minorities. Cancer. 2013;119(3):612–620. 
[PubMed: 22833205] 
Somsouk et al. Page 9
J Natl Cancer Inst. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
19. Lara CL, Means KL, Morwood KD, et al. Colorectal cancer screening interventions in 2 health 
care systems serving disadvantaged populations: screening uptake and cost-effectiveness. Cancer. 
2018;124(21):4130–4136. [PubMed: 30359479] 
20. Liss DT, French DD, Buchanan DR, et al. Outreach for annual colorectal cancer screening: a 
budget impact analysis for community health centers. Am J Prev Med. 2016;50(2):e54–e61. 
[PubMed: 26362405] 
21. Nord E, Johansen R. Concerns for severity in priority setting in health care: a review of trade-off 
data in preference studies and implications for societal willingness to pay for a QALY. Health 
Policy. 2014;116(2–3):281–288. [PubMed: 24690334] 
22. Martin J, Halm EA, Tiro JA, et al. Reasons for lack of diagnostic colonoscopy after positive result 
on fecal immunochemical test in a safety-net health system. Am J Med. 2017;130(1):93.e1–93.e7.
23. Thamarasseril S, Bhuket T, Chan C, et al. The need for an integrated patient navigation pathway to 
improve access to colonoscopy after positive fecal immunochemical testing: a safety-net hospital 
experience. J Community Health. 2017;42(3):551–557. [PubMed: 27796633] 
24. Issaka RB, Avila P, Whitaker E, et al. Population health interventions to improve colorectal cancer 
screening by fecal immunochemical tests: a systematic review. Prev Med. 2019;118:113–121. 
[PubMed: 30367972] 
25. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test 
outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the 
underserved: a randomized clinical trial. JAMA Intern Med. 2013;173(18):1725–1732. [PubMed: 
23921906] 
26. Baker DW, Brown T, Buchanan DR, et al. Comparative effectiveness of a multifaceted intervention 
to improve adherence to annual colorectal cancer screening in community health centers: a 
randomized clinical trial. JAMA Intern Med. 2014;174(8):1235–1241. [PubMed: 24934845] 
27. Singal AG, Gupta S, Tiro JA, et al. Outreach invitations for FIT and colonoscopy improve 
colorectal cancer screening rates: a randomized controlled trial in a safety-net health system. 
Cancer. 2016;122(3):456–463. [PubMed: 26535565] 
28. Goldman SN, Liss DT, Brown T, et al. Comparative effectiveness of multifaceted outreach to 
initiate colorectal cancer screening in community health centers: a randomized controlled trial. J 
Gen Intern Med. 2015;30(8):1178–1184. [PubMed: 25814264] 
29. Coronado GD, Petrik AF, Vollmer WM, et al. Effectiveness of a mailed colorectal cancer screening 
outreach program in community health clinics: the STOP CRC cluster randomized clinical trial. 
JAMA Intern Med. 2018;178(9):1174–1181. [PubMed: 30083752] 
30. Levy BT, Daly JM, Xu Y, et al. Mailed fecal immunochemical tests plus educational materials to 
improve colon cancer screening rates in Iowa Research Network (IRENE) practices. J Am Board 
Fam Med. 2012;25(1):73–82. [PubMed: 22218627] 
31. Myers RE, Sifri R, Hyslop T, et al. A randomized controlled trial of the impact of targeted and 
tailored interventions on colorectal cancer screening. Cancer. 2007;110(9):2083–2091. [PubMed: 
17893869] 
32. Senore C, Ederle A, DePretis G, et al. Invitation strategies for colorectal cancer screening 
programmes: the impact of an advance notification letter. Prev Med. 2015;73:106–111. [PubMed: 
25602908] 
Somsouk et al. Page 10
J Natl Cancer Inst. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
CONSORT (Consolidated Standards of Reporting Trials) flow diagram. FIT = fecal 
immunochemical test.
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Figure 2. 
Cumulative proportion of patients up to date with colorectal cancer screening in the outreach 
intervention and usual care groups. At 1 year, 57.9% of patients in the intervention group 
had returned the FIT kit vs 37.4% in the usual care group. By day 28, outreach statistically 
significantly increased FIT completion (13.3% vs 5.1%). FIT = fecal immunochemical test.
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